Academic Partners

We have been privileged to conduct studies of our PLX cells in collaboration with renowned researchers at internationally recognized institutions. Many of the clinical and preclinical studies of our PLX-PAD cells were conducted in collaboration with leading academics at important centers including the Beth Israel Deaconess Medical Center and Texas A&M University in the U.S., the Charité University Hospital and the Berlin-Brandenburg Center for Regenerative Therapies in Germany, and Hadassah Medical Center in Israel. In October, 2015, we expanded a five-year Collaborative Research Agreement with the Berlin-Brandenburg Center for Regenerative Therapy to include identification of orthopedic indications that may be eligible for development under Europe’s Adaptive Pathways project.

We developed PLX-R18, our second product, in conjunction with Charité Universitätsmedizin Berlin Institute of Medical Immunology, the Berlin-Brandenburg Center for Regenerative Therapies, Hadassah Hebrew University Medical Center, and Indiana University; the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), provided support for the research conducted at Indiana University. We also have a memorandum of understanding with Fukushima Medical University, Fukushima Global Medical Science Center, in Fukushima, Japan, to collaborate on the development of PLX-R18 cells for the treatment of Acute Radiation Syndrome (ARS), and as an adjunct to radiotherapy in cancer patients.